|
1
|
Jemal A, Siegel R, Ward E, et al: Cancer
statistics. CA Cancer J Clin. 58:71–96. 2008.
|
|
2
|
Jass JR: Classification of colorectal
cancer based on correlation of clinical, morphological and
molecular features. Histopathology. 50:113–130. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Tejpar S: The use of molecular markers in
the diagnosis and treatment of colorectal cancer. Best Pract Res
Clin Gastroenterol. 21:1071–1087. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zwick E, Hackel PO, Prenzel N and Ullrich
A: The EGF receptor as central transducer of heterologous signaling
systems. Trends Pharmacol Sci. 20:408–412. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Salomon D, Brandt R, Ciardiello F and
Normanno N: Epidermal growth factor - related peptides and their
receptors in human malignancies. Crit Rev Oncol Hematol.
19:183–232. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Klapper LN, Kirschbaum MH, Sela M and
Yarden Y: Biochemical and clinical implications of the ErbB/HER
signaling network of growth factor receptors. Adv Cancer Res.
77:25–79. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Tol J and Punt CJ: Monoclonal antibodies
in the treatment of metastatic colon cancer: a review. Clin Ther.
32:437–453. 2010. View Article : Google Scholar
|
|
8
|
Modjtahedi H and Essapen S: Epidermal
growth factor receptor inhibitors in cancer treatment: advances,
challenges, and opportunities. Anticancer Drugs. 20:851–855. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kountourakis P, Pavlakis K, Psyrri A, et
al: Clinicopathologic significance of EGFR and Her-2/neu in
colorectal adenocarcinomas. Cancer J. 12:229–236. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Deng Y, Kurland B, Wang J, et al: High
epidermal growth factor receptor expression in metastatic
colorectal cancer lymph nodes may be more prognostic of poor
survival than in primary tumor. Am J Clin Oncol. 32:245–252. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
McKay JA, Murray LJ, Curran S, et al:
Evaluation of the epidermal growth factor receptor (EGFR) in
colorectal tumours and lymph node metastases. Eur J Cancer.
38:2258–2264. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Spano JP, Lagorce C, Atlan D, et al:
Impact of EGFR expression on colorectal cancer patient prognosis
and survival. Ann Oncol. 16:102–108. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Galizia G, Lieto E, Ferraraccio F, et al:
Prognostic significance of epidermal growth factor receptor
expression in colon cancer patients undergoing curative surgery.
Ann Surg Oncol. 13:823–835. 2006. View Article : Google Scholar
|
|
14
|
Resnic MB, Routhier J, Konkin T, Sabo E
and Pricolo VE: Epidermal growth factor receptor, c-MET,
beta-catenin, and p53 expression as prognostic indicators in stage
II colon cancer: a tissue microarray study. Clin Cancer Res.
10:3069–3075. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Iacopetta B: Are there two sites to
colorectal cancer? Int J Cancer. 101:403–408. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sugai T, Habano W, Jiao YF, Tsukahara M,
Takeda Y, Otsuka K and Nakamura S: Analysis of molecular
alterations in left- and right- sided colorectal carcinomas reveals
distinct pathways of carcinogenesis. J Mol Diagn. 8:193–201. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Nawa T, Kato J, Kawamoto H, et al:
Differences between right and left-sided colon cancer in patient
characteristics, cancer morphology and histology. J Gastroenderol
Hepatol. 23:418–423. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Papagiorgis PC, Zizi AE, Tseleni S, et al:
Site impact on colorectal cancer biological behavior in terms of
clinicopathological and molecular features. J BUON. 16:84–92.
2011.PubMed/NCBI
|
|
19
|
Menguid R, Slidell MB, Wolfgang L, Chang
DC and Ahuja N: Is there a difference in survival between right-
versus left-sided colon cancers? Ann Surg Oncol. 15:2388–2394.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Elsaleh H, Joseph D, Grieu F, Zeps N, Spry
N and Iacopetta B: Association of tumour site and sex with survival
benefit from adjuvant chemotherapy in CRC. Lancet. 355:1745–1750.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zlobec I, Steele R, Michel R, Compton C,
Lugli A and Jass J: Scoring of p53, VEGF, Bcl-2 and APAF-1
immunohistochemistry and interobserver reliability in colorectal
cancer. Mod Pathol. 19:1236–1242. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lee JC, Wang ST, Chow NH and Yang HB:
Investigation of the prognostic value of coexpressed erbB family
members for the survival of colorectal cancer patients after
curative surgery. Eur J Cancer. 38:1065–1071. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Takeuchi K, Kuwano H, Tsuzuki Y, Ando T,
Sekihara M, Hara T and Asao T: Clinicopathological characteristics
of poorly differentiated adenocarcinoma of the colon and rectum.
Hepatogastroenterology. 51:1698–1702. 2004.PubMed/NCBI
|
|
24
|
Russo A, Bazan V, Iacopetta D, Kerr D,
Soussi T and Gebbia N: The TP53 colorectal cancer international
collaborative study on the prognostic and predictive significance
of p53 mutation: influence of tumor site, type of mutation, and
adjuvant treatment. J Clin Oncol. 23:7518–7528. 2005. View Article : Google Scholar
|
|
25
|
Kastrinakis WV, Ramchurren N, Rieger KM,
Hest DT, Loda M, Steel G and Summerhayes IC: Increased incidence of
p53 mutations is associated with hepatic metastasis in colorectal
neoplastic progression. Oncogene. 11:647–652. 1995.PubMed/NCBI
|
|
26
|
Oden-Gangloff A, Di Fiore F, Bibeau F, et
al: TP53 mutations predict disease control in metastatic colorectal
cancer treated with cetuximab-based chemotherapy. Br J Cancer.
100:1330–1335. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Chun P and Wainberg A: Adjuvant
chemotherapy for stage II colon cancer: the role of molecular
markers in choosing therapy. Gastrointest Cancer Res. 3:191–196.
2009.PubMed/NCBI
|
|
28
|
O’Connell MJ, Lavery I, Yothers G, et al:
Relationship between tumor gene expression and recurrence in four
independent studies of patients with stage II/III colon cancer
treated with surgery alone or surgery plus adjuvant fluorouracil
plus leucovorin. J Clin Oncol. 28:3937–3944. 2010.PubMed/NCBI
|
|
29
|
Bacolod MD and Barany F: Molecular
profiling of colon tumors: the search for clinically relevant
biomarkers of progression, prognosis, therapeutics, and
predisposition. Ann Surg Oncol. 2011. View Article : Google Scholar
|
|
30
|
Allegra CJ, Jessup JF, Somerfield MR, et
al: American Society of Clinical Oncology provisional clinical
opinion: testing for KRAS gene mutations in patients with
metastatic colorectal carcinoma to predict response to
anti-epidermal growth factor receptor monoclonal antibody therapy.
J Clin Oncol. 27:2091–2096. 2009. View Article : Google Scholar
|
|
31
|
Laurent-Puig P, Cayre A, Manceau G, et al:
Analysis of PTEN, BRAF, and EGFR status in determining benefit from
cetuximab therapy in wild-type KRAS metastatic colon cancer. J Clin
Oncol. 27:5924–5930. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Elnatan J, Coh HS and Smith DR: C-KI-RAS
activation and the biological behaviour of proximal and distal
colonic adenocarcinomas. Eur J Cancer. 32A:491–497. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Chang MH, Lee IK, Si Y, Lee KS, Woo IS and
Byun JH: Clinical impact of K-ras mutation in colorectal cancer
patients treated with adjuvant FOLFOX. Cancer Chemother Pharmacol.
68:317–323. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Dukes C and Bussey H: The spread of rectal
cancer and its effect on prognosis. Br J Cancer. 12:309–320. 1958.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Atkins D, Reiffen KA, Tegtmeier CL,
Winther H, Bonato MS and Störkel S: Immunohistochemical detection
of EGFR in paraffin-embedded tumor tissue: variation in staining
intensity due to choice of fixative and storage time of tissue
sections. J Histochem Cytochem. 58:893–901. 2004. View Article : Google Scholar
|
|
36
|
Tampellini M, Longo M, Cappia S, et al:
Co-expression of EGFR receptor, TGFa and S6 kinase is significantly
associated with colorectal carcinomas with distant metastases at
diagnosis. Virchows Arch. 450:321–328. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Rigopoulos DN, Tsiambas E, Lazaris AC, et
al: Deregulation of EGFR/VEGF/HIF-1a signaling pathway in colon
adenocarcinoma based on tissue microarrays analysis. J BUON.
15:107–115. 2010.PubMed/NCBI
|
|
38
|
Messa C, Russo F, Caruso MG and Di Leo A:
EGF, TGF-alpha, and EGF-R in human colorectal adenocarcinoma. Acta
Oncol. 37:285–289. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Benedix F, Schmidt U, Mroczkowski P,
Gastinger I, Lippert H and Kube R: Colon carcinoma - classification
into right and left sided cancer or according to colonic subsite? -
Analysis of 29,568 patients. Eur J Surg Oncol. 37:134–139. 2011.
View Article : Google Scholar : PubMed/NCBI
|
